Search

Your search keyword '"Perini, Tommaso"' showing total 148 results
Start Over Author "Perini, Tommaso"
148 results on '"Perini, Tommaso"'

2. Dual PAK4-NAMPT Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldenström Macroglobulinemia

Author

Li, Na, Lopez, Michael A., Linares Gómez, María, Kumar, Subodh, Oliva, Stefania, Martinez-Lopez, Joaquin, Xu, Lian, Xu, Yan, Perini, Tommaso, Senapedis, William, Baloglu, Erkan, Shammas, Masood A., Hunter, Zachary, Anderson, Kenneth C., Treon, Steven P., Munshi, Nikhil C., Fulciniti, Mariateresa, Li, Na, Lopez, Michael A., Linares Gómez, María, Kumar, Subodh, Oliva, Stefania, Martinez-Lopez, Joaquin, Xu, Lian, Xu, Yan, Perini, Tommaso, Senapedis, William, Baloglu, Erkan, Shammas, Masood A., Hunter, Zachary, Anderson, Kenneth C., Treon, Steven P., Munshi, Nikhil C., and Fulciniti, Mariateresa

Abstract

Purpose: p21-activated kinase 4 (PAK4) plays a significant biological and functional role in a number of malignancies, including multiple myeloma (MM). On the basis of our promising findings in MM, we here characterize PAK4 expression and role in WM cells, as well effect of dual PAK4-NAMPT inhibitor (KPT-9274) against WM cell growth and viability. Experimental Design: We have analyzed mRNA and protein expression levels of PAK4 in WM cells, and used loss-offunction approach to investigate its contribution to WM cell viability. We have further tested the in vitro and in vivo effect of KPT-9274 against WM cell growth and viability. Results: We report here high-level expression and functional role of PAK4 in WM, as demonstrated by shRNA-mediated knockdown; and significant impact of KPT-9274 on WM cell growth and viability. The growth inhibitory effect of KPT-9274 was associated with decreased PAK4 expression and NAMPT activity, as well as induction of apoptosis. Interestingly, in WM cell lines treated with KPT-9274, we detected a significant impact on DNA damage and repair genes. Moreover, we observed that apart from inducing DNA damage, KPT-9274 specifically decreased RAD51 and the double-strand break repair by the homologous recombination pathway. As a result, when combined with a DNA alkylating agents bendamustine and melphalan, KPT-9274 provided a synergistic inhibition of cell viability in WM cell lines and primary patient WM cells in vitro and in vivo. Conclusions: These results support the clinical investigation of KPT-9274 in combination with DNA-damaging agent for treatment of WM., NIH, Department of Veterans Affairs Merit Review Award, Depto. de Bioquímica y Biología Molecular, Fac. de Farmacia, TRUE, pub

Published
2024

3. Monoclonal Antibodies in Smoldering Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance: Current Status and Future Directions.

Author

Ferla, Valeria, Farina, Francesca, Perini, Tommaso, Marcatti, Magda, and Ciceri, Fabio

Subjects
MULTIPLE myeloma, MONOCLONAL antibodies, THERAPEUTICS, DISEASE progression, PROGNOSIS
Abstract

Monoclonal antibodies (MoAbs) targeting several cellular receptors have significantly improved the prognosis of multiple myeloma (MM). Their high effectiveness and safety raise the question of whether earlier therapeutic intervention in monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) influences the natural course of the disease. MM is preceded by clinically recognized conditions such as MGUS and SMM. Numerous studies are investigating the disease biology and immune profile of SMM and MGUS to unravel the intricate relationship between immunosurveillance and disease progression. The standard approach to MGUS and SMM remains close observation. Early studies indicate benefits in terms of progression or even survival for promptly treating high-risk SMM patients. Ongoing debates are focused on which patients with SMM and MGUS to treat, as well as on determining the optimal therapeutic approach. The first approach aims to cure by attempting to eliminate the pathological clone, while the second approach is preventive, aiming to manage disease progression to active MM and restore the immune system. In this review, we focus on the available and emerging data on early treatment, particularly with MoAbs alone or in combination with other therapies, in SMM and MGUS patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

4. Nanosphere’s Verigene® Blood Culture Assay to Detect Multidrug-Resistant Gram-Negative Bacterial Outbreak: A Prospective Study on 79 Hematological Patients in a Country with High Prevalence of Antimicrobial Resistance

Author

Greco, Raffaella, Barbanti, Maria Chiara, Mancini, Nicasio, Infurnari, Laura, Pasciuta, Renée, Forcina, Alessandra, Oltolini, Chiara, Casirati, Gabriele, Mannina, Daniele, Giglio, Fabio, Messina, Carlo, Morelli, Mara, Lorentino, Francesca, Mastaglio, Sara, Perini, Tommaso, Vago, Luca, Scarpellini, Paolo, Carrabba, Matteo Giovanni, Stanghellini, Maria Teresa Lupo, Marktel, Sarah, Assanelli, Andrea, Bernardi, Massimo, Corti, Consuelo, Peccatori, Jacopo, Clementi, Massimo, and Ciceri, Fabio

Published
2019
Full Text
View/download PDF

6. P-362 ID2 acts as a novel tumor suppressor in MM by inhibition of TCF3 transcriptional activity

Author

Perini, Tommaso, primary, Yao, Yao, additional, Ng, Jessica Fong, additional, Deng, Shuhui, additional, Schavgoulidze, Anais, additional, Binder, Moritz, additional, Young, Ryan, additional, Knudson, Mei, additional, Epstein, Charles, additional, Gulla, Annamaria, additional, Morelli, Eugenio, additional, Szalat, Raphael, additional, Samur, Mehmet, additional, Anderson, Kenneth, additional, Fulciniti, Mariateresa, additional, and Munshi, Nikhil, additional

Published
2023
Full Text
View/download PDF

8. P965: STEM-CELL MOBILIZATION WITH CYCLOPHOSPHAMIDE 4 G/M2 ALLOWS COLLECTION OF HIGH NUMBERS OF CD34+ CELLS AFTER DARA-VTD INDUCTION FOR MULTIPLE MYELOMA

Author

Perini, Tommaso, primary, Liberatore, Carmine, additional, Virginia, Girlando, additional, Passeri, Cecilia, additional, Ferla, Valeria, additional, Iuliani, Ornella, additional, Orsini, Alessia, additional, Montanaro, Guido, additional, Farina, Francesca, additional, Nicola, Alessandro DI, additional, Marktel, Sarah, additional, Pulini, Stefano, additional, Santarone, Stella, additional, Accorsi, Patrizia, additional, Ciceri, Fabio, additional, Ianni, Mauro DI, additional, and Marcatti, Magda, additional

Published
2023
Full Text
View/download PDF

9. PB2575: HIGH INCIDENCE OF RESPIRATORY TRACT INFECTIONS FOLLOWING COVID-19 WAVES IN PATIENTS WITH PLASMA CELL DYSCRASIAS

Author

Farina, Francesca, primary, Marktel, Sarah, additional, Ferla, Valeria, additional, Clerici, Daniela, additional, Daniele, Sannipoli, additional, Perini, Tommaso, additional, Catalano, Gloria, additional, Oltolini, Chiara, additional, Stanghellini, Maria Teresa Lupo, additional, Corti, Consuelo, additional, Ciceri, Fabio, additional, and Marcatti, Magda, additional

Published
2023
Full Text
View/download PDF

10. Higher cyclophosphamide dose grants optimal stem cell collection after daratumumab-based induction in multiple myeloma

Author

Liberatore, Carmine, primary, Perini, Tommaso, additional, Passeri, Cecilia, additional, Ferla, Valeria, additional, Fioritoni, Francesca, additional, Girlando, Virginia, additional, Iuliani, Ornella, additional, Orsini, Alessia, additional, Montanaro, Guido, additional, Farina, Francesca, additional, Di Nicola, Alessandro, additional, Nitti, Rosamaria, additional, Pulini, Stefano, additional, Mastaglio, Sara, additional, Santarone, Stella, additional, Coppola, Milena, additional, Marktel, Sarah, additional, Accorsi, Patrizia, additional, Ciceri, Fabio, additional, Marcatti, Magda, additional, and Di Ianni, Mauro, additional

Published
2023
Full Text
View/download PDF

11. Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT

Author

Noviello, Maddalena, Manfredi, Francesco, Ruggiero, Eliana, Perini, Tommaso, Oliveira, Giacomo, Cortesi, Filippo, De Simone, Pantaleo, Toffalori, Cristina, Gambacorta, Valentina, Greco, Raffaella, Peccatori, Jacopo, Casucci, Monica, Casorati, Giulia, Dellabona, Paolo, Onozawa, Masahiro, Teshima, Takanori, Griffioen, Marieke, Halkes, Constantijn J. M., Falkenburg, J. H. F., Stölzel, Friedrich, Altmann, Heidi, Bornhäuser, Martin, Waterhouse, Miguel, Zeiser, Robert, Finke, Jürgen, Cieri, Nicoletta, Bondanza, Attilio, Vago, Luca, Ciceri, Fabio, and Bonini, Chiara

Published
2019
Full Text
View/download PDF

12. DISSECTING THE ROLE OF CLPP IN MULTIPLE MYELOMA

Author

PERINI, TOMMASO and Perini, Tommaso

Abstract

Despite the efficacy of targeted treatments, multiple myeloma (MM) is still incurable, urging to identify novel vulnerabilities to design more effective therapies. Mitochondria are emerging therapeutic targets in oncology for their crucial role not only as cellular powerhouses, but also in signalling, redox homeostasis, initiation of apoptosis, production of metabolites, and supply of biosynthetic precursors. Owing to intensive immunoglobulin production, myeloma cells are heavily reliant on protein homeostasis and experience significant exposure to mitochondrial stressors. We hypothesized that myeloma cells depend on the prototypical mitochondrial stress-adaptive pathway, the mitochondrial unfolded protein response (UPRmt), for their fitness and survival. We tested its activation status and its manipulation as a possible tool against myeloma. We found that while a clear upregulation of the UPRmt signature is evident in MM, its regulation is independent of the master transcription factor ATF5, so far believed to mediate the mammalian UPRmt. One of the key players of the UPRmt and gatekeeper of mitochondrial homeostasis is ClpP, a resident mitochondrial protease suggested to maintain oxidative phosphorylation efficiency. Prompted by its distinctive expression in malignant plasma cells, we investigated the role of ClpP in multiple myeloma cells and tested it as a possible anti-myeloma target. We found that ClpP downregulation leads to disappearance of MM cells from culture due to apoptosis or cell cycle arrest. Surprisingly, toxicity extends to glycolytic cell lines and we demonstrated that ClpP knockdown has no effects on mitochondrial oxygen consumption by MM cells, thus unveiling an energy-independent vulnerability. By combining RNA-seq, proteomics, and metabolomics we identified unprecedented and unexpected cellular features regulated by ClpP, including protein translation both in the cytosol and in mitochondria, impairment of fatty acid metabolism with accumulation of acyl-carnitines and long chain unsaturated fatty acids, deregulation of the polyamine pathway with depletion of spermine, spermidine and putrescine. Intriguingly, we also detected a strong impact on interferon-regulated pathways, hinting at mitochondria and ClpP as possible tools to manipulate MM immunogenicity. Our data suggest that ClpP is vital to MM cells due to a novel non-bioenergetic function, and pave the way for its further evaluation as a therapeutic target. Despite the efficacy of targeted treatments, multiple myeloma (MM) is still incurable, urging to identify novel vulnerabilities to design more effective therapies. Mitochondria are emerging therapeutic targets in oncology for their crucial role not only as cellular powerhouses, but also in signalling, redox homeostasis, initiation of apoptosis, production of metabolites, and supply of biosynthetic precursors. Owing to intensive immunoglobulin production, myeloma cells are heavily reliant on protein homeostasis and experience significant exposure to mitochondrial stressors. We hypothesized that myeloma cells depend on the prototypical mitochondrial stress-adaptive pathway, the mitochondrial unfolded protein response (UPRmt), for their fitness and survival. We tested its activation status and its manipulation as a possible tool against myeloma. We found that while a clear upregulation of the UPRmt signature is evident in MM, its regulation is independent of the master transcription factor ATF5, so far believed to mediate the mammalian UPRmt. One of the key players of the UPRmt and gatekeeper of mitochondrial homeostasis is ClpP, a resident mitochondrial protease suggested to maintain oxidative phosphorylation efficiency. Prompted by its distinctive expression in malignant plasma cells, we investigated the role of ClpP in multiple myeloma cells and tested it as a possible anti-myeloma target. We found that ClpP downregulation leads to disappearance of MM cells from culture due to apoptosis or cell cycle arrest. Surprisingly, toxicity extends to glycolytic cell lines and we demonstrated that ClpP knockdown has no effects on mitochondrial oxygen consumption by MM cells, thus unveiling an energy-independent vulnerability. By combining RNA-seq, proteomics, and metabolomics we identified unprecedented and unexpected cellular features regulated by ClpP, including protein translation both in the cytosol and in mitochondria, impairment of fatty acid metabolism with accumulation of acyl-carnitines and long chain unsaturated fatty acids, deregulation of the polyamine pathway with depletion of spermine, spermidine and putrescine. Intriguingly, we also detected a strong impact on interferon-regulated pathways, hinting at mitochondria and ClpP as possible tools to manipulate MM immunogenicity. Our data suggest that ClpP is vital to MM cells due to a novel non-bioenergetic function, and pave the way for its further evaluation as a therapeutic target.

Published
2022

14. Minimal residual disease detection by next-generation sequencing in multiple myeloma: Promise and challenges for response-adapted therapy

Author

Ferla, Valeria, primary, Antonini, Elena, additional, Perini, Tommaso, additional, Farina, Francesca, additional, Masottini, Serena, additional, Malato, Simona, additional, Marktel, Sarah, additional, Lupo Stanghellini, Maria Teresa, additional, Tresoldi, Cristina, additional, Ciceri, Fabio, additional, and Marcatti, Magda, additional

Published
2022
Full Text
View/download PDF

18. B Cell Transcriptional Coactivator POU2AF1 (BOB-1) Is an Early Transcription Factor Modulating the Protein Synthesis and Ribosomal Biogenesis in Multiple Myeloma: With Therapeutic Implication

Author

Chyra, Zuzana, primary, Samur, Mehmet K., additional, Aktas-Samur, Anil, additional, Yao, Yao, additional, Derebail, Sanika, additional, Perini, Tommaso, additional, Xu, Yan, additional, Morelli, Eugenio, additional, Adamia, Sophia, additional, Park, Woojun D, additional, Charles, Lin, additional, Shirasaki, Ryosuke, additional, Shammas, Masood A., additional, Mitsiades, Constantine S., additional, Hajek, Roman, additional, Fulciniti, Mariateresa, additional, and Munshi, Nikhil C., additional

Published
2021
Full Text
View/download PDF

21. P-046: B cell transcriptional coactivator POU2AF1 (BOB-1) modulates the protein synthesis and offers a potential vulnerability in multiple myeloma.

Author

Chyra, Zuzana, primary, Samur, Mehmet K, additional, Samur, Anil, additional, Yao, Yao, additional, Derebail, Sanika, additional, Perini, Tommaso, additional, Xu, Yan, additional, Morelli, Eugenio, additional, Adamia, Sophia, additional, Park, Woojun D, additional, Lin, Charles, additional, Shirasaki, Ryosuke, additional, Mitsiades, Constantine, additional, Shammas, Masood, additional, Hájek, Roman, additional, Fulciniti, Mariateresa, additional, and Munshi, Nikhil C., additional

Published
2021
Full Text
View/download PDF

22. Treosulfan-Based Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation: Long-Term Results From a Phase 2 Clinical Trial

Author

Lazzari, Lorenzo, primary, Ruggeri, Annalisa, additional, Lupo Stanghellini, Maria Teresa, additional, Mastaglio, Sara, additional, Messina, Carlo, additional, Giglio, Fabio, additional, Lorusso, Alessandro, additional, Perini, Tommaso, additional, Piemontese, Simona, additional, Marcatti, Magda, additional, Lorentino, Francesca, additional, Xue, Elisabetta, additional, Clerici, Daniela, additional, Corti, Consuelo, additional, Bernardi, Massimo, additional, Assanelli, Andrea, additional, Greco, Raffaella, additional, Ciceri, Fabio, additional, and Peccatori, Jacopo, additional

Published
2021
Full Text
View/download PDF

24. Minimal residual disease detection by next-generation sequencing in multiple myeloma: Promise and challenges for responseadapted therapy.

Author

Ferla, Valeria, Antonini, Elena, Perini, Tommaso, Farina, Francesca, Masottini, Serena, Malato, Simona, Marktel, Sarah, Lupo Stanghellini, Maria Teresa, Tresoldi, Cristina, Ciceri, Fabio, and Marcatti, Magda

Subjects
MULTIPLE myeloma, NUCLEOTIDE sequencing, CHRONIC myeloid leukemia, INCURABLE diseases, DRUG bioavailability, TESTICULAR cancer
Abstract

Assessment of minimal residual disease (MRD) is becoming a standard diagnostic tool for curable hematological malignancies such as chronic and acute myeloid leukemia. Multiple myeloma (MM) remains an incurable disease, as a major portion of patients even in complete response eventually relapse, suggesting that residual disease remains. Over the past decade, the treatment landscape of MM has radically changed with the introduction of new effective drugs and the availability of immunotherapy, including targeted antibodies and adoptive cell therapy. Therefore, conventional serological and morphological techniques have become suboptimal for the evaluation of depth of response. Recently, the International Myeloma Working Group (IMWG) introduced the definition of MRD negativity as the absence of clonal Plasma cells (PC) with a minimum sensitivity of <10-5 either by next-generation sequencing (NGS) using the LymphoSIGHT platform (Sequenta/Adaptative) or by next-generation flow cytometry (NGF) using EuroFlow approaches as the reference methods. While the definition of the LymphoSIGHT platform (Sequenta/Adaptive) as the standard method derives from its large use and validation in clinical studies on the prognostic value of NGS-based MRD, other commercially available options exist. Recently, the LymphoTrack assay has been evaluated in MM, demonstrating a sensitivity level of 10-5, hence qualifying as an alternative effective tool for MRD monitoring in MM. Here, we will review state-of-the-art methods for MRD assessment by NGS. We will summarize how MRD testing supports clinical trials as a useful tool in dynamic risk-adapted therapy. Finally, we will also discuss future promise and challenges of NGS-based MRD determination for clinical decision-making. In addition, we will present our real-life single-center experience with the commercially available NGS strategy LymphoTrack-MiSeq. Even with the limitation of a limited number of patients, our results confirm the LymphoTrack-MiSeq platform as a cost-effective, readily available, and standardized workflow with a sensitivity of 10-5. Our real-life data also confirm that achieving MRD negativity is an important prognostic factor in MM. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

25. The Immunity‐malignancy equilibrium in multiple myeloma: lessons from oncogenic events in plasma cells.

Author

Perini, Tommaso, Materozzi, Maria, and Milan, Enrico

Subjects
*MULTIPLE myeloma, *PLASMA cells, *CYTOLOGY, *BONE marrow, *ANTIBODY formation, *ENDOPLASMIC reticulum
Abstract

Multiple myeloma (MM) is a malignancy of plasma cells (PC) that grow within the bone marrow and maintain massive immunoglobulin (Ig) production. Disease evolution is driven by genetic lesions, whose effects on cell biology and fitness underlie addictions and vulnerabilities of myeloma cells. Several genes mutated in myeloma are strictly involved in dictating PC identity and antibody factory function. Here, we evaluate the impact of mutations in IRF4, PRDM1, and XBP1, essential transcription factors driving the B to PC differentiation, on MM cell biology and homeostasis. These factors are highly specialized, with limited overlap in their downstream transcriptional programs. Indeed, IRF4 sustains metabolism, survival, and proliferation, while PRDM1 and XBP1 are mainly responsible for endoplasmic reticulum expansion and sustained Ig secretion. Interestingly, IRF4 undergoes activating mutations and translocations, while PRDM1 and XBP1 are hit by loss‐of‐function events, raising the hypothesis that containment of the secretory program, but not its complete extinction, may be beneficial to malignant PCs. Finally, recent studies unveiled that also the PRDM1 target, FAM46C/TENT5C, an onco‐suppressor uniquely and frequently mutated or deleted in myeloma, is directly and potently involved in orchestrating ER homeostasis and secretory activity. Inactivating mutations found in this gene and its interactors strengthen the notion that reduced secretory capacity confers advantage to myeloma cells. We believe that dissection of the evolutionary pressure on genes driving PC‐specific functions in myeloma will disclose the cellular strategies by which myeloma cells maintain an equilibrium between antibody production and survival, thus unveiling novel therapeutic targets. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

26. The Interaction of the Tumor Suppressor FAM46C with p62 and FNDC3 Proteins Integrates Protein and Secretory Homeostasis

Author

Fucci, Chiara, primary, Resnati, Massimo, additional, Riva, Elena, additional, Perini, Tommaso, additional, Ruggieri, Elena, additional, Orfanelli, Ugo, additional, Paradiso, Francesca, additional, Cremasco, Floriana, additional, Raimondi, Andrea, additional, Pasqualetto, Elena, additional, Nuvolone, Mario, additional, Rampoldi, Luca, additional, Cenci, Simone, additional, and Milan, Enrico, additional

Published
2020
Full Text
View/download PDF

27. YWHAE/14-3-3ε expression impacts the protein load, contributing to proteasome inhibitor sensitivity in multiple myeloma

Author

Xu, Yan, primary, Fulciniti, Mariateresa, additional, Samur, Mehmet K., additional, Ho, Matthew, additional, Deng, Shuhui, additional, Liu, Lanting, additional, Wen, Kenneth, additional, Yu, Tengteng, additional, Chyra, Zuzana, additional, Dereibal, Sanika, additional, Zhang, Li, additional, Yao, Yao, additional, Chakraborty, Chandraditya, additional, Morelli, Eugenio, additional, Li, Na, additional, Lopez, Michael A., additional, Perini, Tommaso, additional, Mu, Shidai, additional, An, Gang, additional, Alonso, Rafael, additional, Bianchi, Giada, additional, Tai, Yu-Tzu, additional, Anderson, Kenneth C., additional, Qiu, Lugui, additional, and Munshi, Nikhil C., additional

Published
2020
Full Text
View/download PDF

28. YWHAE/14-3-3ε expression impacts the proteasome load contributing to proteasome inhibitor sensitivity in multiple myeloma

Author

Xu, Yan, primary, Samur, Mehmet, additional, Ho, Matthew, additional, deng, shuhui, additional, liu, lanting, additional, Wen, Kenneth, additional, Bianchi, Giada, additional, Yu, Tengteng, additional, Chyra, Zuzana, additional, Derebail, Sanika, additional, Perini, Tommaso, additional, Morelli, Eugenio, additional, Chakraborty, Chandraditya, additional, Anderson, Kenneth C., additional, Qiu, Lugui, additional, Fulciniti, Mariateresa, additional, and Munshi, Nikhil, additional

Published
2019
Full Text
View/download PDF

29. Dual PAK4-NAMPT Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldenström Macroglobulinemia

Author

Li, Na, primary, Lopez, Michael A., additional, Linares, Maria, additional, Kumar, Subodh, additional, Oliva, Stefania, additional, Martinez-Lopez, Joaquin, additional, Xu, Lian, additional, Xu, Yan, additional, Perini, Tommaso, additional, Senapedis, William, additional, Baloglu, Erkan, additional, Shammas, Masood A., additional, Hunter, Zachary, additional, Anderson, Kenneth C., additional, Treon, Steven P., additional, Munshi, Nikhil C., additional, and Fulciniti, Mariateresa, additional

Published
2019
Full Text
View/download PDF

31. Dysregulated Translational Control Is a Central Feature of MM Mediated By 14-3-3ε Interactome Promoting Multiple Myeloma Cell Growth and Viability

Author

Xu, Yan, primary, Fulciniti, Mariateresa, additional, Ho, Matthew, additional, Samur, Mehmet Kemal, additional, Lopez, Michael A, additional, Li, Na, additional, Bianchi, Giada, additional, Szalat, Raphael, additional, Lin, Jianhong, additional, Perini, Tommaso, additional, Talluri, Srikanth, additional, Yu, Tengteng, additional, Wen, Kenneth, additional, Liu, Jiye, additional, Zhang, Li, additional, Lin, Liang, additional, Xing, Lijie, additional, An, Gang, additional, Tai, Yu-Tzu, additional, Anderson, Kenneth, additional, Qiu, Lugui, additional, and Munshi, Nikhil, additional

Published
2018
Full Text
View/download PDF

32. Exhausted Central Memory and Memory Stem T Cells Specific for Leukemia Infiltrate the Bone Marrow of AML Patients Relapsing after Allogeneic HSCT

Author

Manfredi, Francesco, primary, Noviello, Maddalena, additional, Ruggiero, Eliana, additional, Perini, Tommaso, additional, Oliveira, Giacomo, additional, Cortesi, Filippo, additional, De Simone, Pantaleo, additional, Toffalori, Cristina, additional, Gambacorta, Valentina, additional, Greco, Raffaella, additional, Peccatori, Jacopo, additional, Casucci, Monica, additional, Casorati, Giulia, additional, Dellabona, Paolo, additional, Cieri, Nicoletta, additional, Bondanza, Attilio, additional, Vago, Luca, additional, Ciceri, Fabio, additional, and Bonini, Chiara, additional

Published
2018
Full Text
View/download PDF

33. Inhibitor of DNA Binding 2 (ID2) Plays a Key Tumor Suppressor Role in Promoting Oncogenic Transformation in Multiple Myeloma

Author

Perini, Tommaso, primary, Szalat, Raphael, additional, Samur, Mehmet Kemal, additional, Fulciniti, Mariateresa, additional, Lopez, Michael A, additional, Lawlor, Matthew, additional, Ott, Christopher J., additional, Li, Na, additional, Xu, Yan, additional, Wen, Kenneth, additional, Amodio, Nicola, additional, Morelli, Eugenio, additional, Anderson, Kenneth, additional, Ciceri, Fabio, additional, and Munshi, Nikhil, additional

Published
2018
Full Text
View/download PDF

34. Functional Role of Linc-RNAs in Multiple Myeloma: Linc-MIR17HG Affects Fatty Acid Biosynthesis Via transcriptional Regulation of ACC1 with Potential Therapeutic Implications

Author

Morelli, Eugenio, primary, Fulciniti, Mariateresa, additional, Samur, Mehmet Kemal, additional, Scionti, Francesca, additional, Gulla, Annamaria, additional, Amodio, Nicola, additional, Bianchi, Giada, additional, Perini, Tommaso, additional, Federico, Cinzia, additional, Lopez, Michael A, additional, Di Martino, Maria Teresa, additional, Tagliaferri, Pierosandro, additional, Tassone, Pierfrancesco, additional, Anderson, Kenneth, additional, and Munshi, Nikhil, additional

Published
2018
Full Text
View/download PDF

36. PAK4 Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldestrostom Macroglobulinemia

Author

Li, Na, primary, Fulciniti, Mariateresa, additional, Lopez, Michael A, additional, Perini, Tommaso, additional, Szalat, Raphael, additional, Kumar, Subodh, additional, Samur, Mehmet Kemal, additional, Xu, Lian, additional, Xu, Yan, additional, Senapedis, William, additional, Baloglu, Erkan, additional, Oliva, Stefania, additional, Shammas, Masood A., additional, Hunter, Zachary, additional, Anderson, Kenneth C, additional, Treon, Steven P, additional, and Munshi, Nikhil, additional

Published
2017
Full Text
View/download PDF

38. Voriconazole and Non-Melanoma Skin Cancer after Allogeneic HSCT: Results of a Prospective Dedicated Follow-up Program in 302 Patients

Author

Lupo-Stanghellini, Maria Teresa, primary, Greco, Raffaella, additional, Assanelli, Andrea Angelo, additional, Perini, Tommaso, additional, Guggiari, Elena, additional, Lorentino, Francesca, additional, Piemontese, Simona, additional, Morelli, Mara, additional, Antonarelli, Gabriele, additional, Giglio, Fabio, additional, Dalto, Serena Camilla, additional, Mastaglio, Sara, additional, Sala, Elisa, additional, Pavesi, Francesca, additional, Carrabba, Matteo Giovanni, additional, Marcatti, Magda, additional, Marktel, Sarah, additional, Girlanda, Stefania, additional, Messina, Carlo, additional, Vago, Luca, additional, Lunghi, Francesca, additional, Bernardi, Massimo, additional, Corti, Consuelo, additional, Bonini, Chiara, additional, Peccatori, Jacopo, additional, and Ciceri, Fabio, additional

Published
2016
Full Text
View/download PDF

39. Biomarkers Predicting Acute GvHD and Transplant Outcomes in 120 Consecutive Allogeneic HSCT Recipients

Author

Greco, Raffaella, primary, Lorentino, Francesca, additional, Lupo Stanghellini, Maria Teresa, additional, Cheyenne Vaccari, Linda, additional, Nitti, Rosamaria, additional, Barbanti, Maria Chiara, additional, Forcina, Alessandra, additional, Giglio, Fabio, additional, Morelli, Mara, additional, Mannina, Daniele, additional, Perini, Tommaso, additional, Mastaglio, Sara, additional, Piemontese, Simona, additional, Assanelli, Andrea Angelo, additional, Marktel, Sarah, additional, Carrabba, Matteo Giovanni, additional, Vago, Luca, additional, Corti, Consuelo, additional, Bernardi, Massimo, additional, Ciceri, Fabio, additional, and Peccatori, Jacopo, additional

Published
2016
Full Text
View/download PDF

40. Post-Transplant Treatment with Ponatinib for Patients with High-Risk Philadelphia Chromosome Positive Leukemia

Author

Lupo-Stanghellini, Maria Teresa, primary, Lunghi, Francesca, additional, Assanelli, Andrea Angelo, additional, Guggiari, Elena, additional, Greco, Raffaella, additional, Morelli, Mara, additional, Perini, Tommaso, additional, Dalto, Serena Camilla, additional, Sala, Elisa, additional, Lorentino, Francesca, additional, Piemontese, Simona, additional, Pavesi, Francesca, additional, Mastaglio, Sara, additional, Mannina, Daniele, additional, Messina, Carlo, additional, Vago, Luca, additional, Marktel, Sarah, additional, Carrabba, Matteo Giovanni, additional, Marcatti, Magda, additional, Bernardi, Massimo, additional, Corti, Consuelo, additional, Bonini, Chiara, additional, Peccatori, Jacopo, additional, Ciceri, Fabio, additional, and Giglio, Fabio, additional

Published
2016
Full Text
View/download PDF

41. Escalated Dose-Rates of Total Marrow Irradiation (TMI) Combined with Treosulfan and Fludarabine-Based Conditioning Chemotherapy Regimen for Chemosensitive Advanced Multiple Myeloma (MM) Patients Undergoing a Matched Allogeneic Stem-Cell Transplantation: First Results of a Phase I/II Prospective Monocentric Study (TrRaMM TMI)

Author

Assanelli, Andrea Angelo, primary, Lorentino, Francesca, additional, Marcatti, Magda, additional, Chiara, Anna, additional, Perini, Tommaso, additional, Lupo Stanghellini, Maria Teresa, additional, Giglio, Fabio, additional, Morelli, Mara, additional, Greco, Raffaella, additional, Broggi, Sara, additional, Cattaneo, Mauro, additional, Peccatori, Jacopo, additional, Bonini, Chiara, additional, Di Muzio, Nadia, additional, and Ciceri, Fabio, additional

Published
2016
Full Text
View/download PDF

42. Disease Risk Index (DRI) Score Stratification and Composite End-Point GvHD-Free Relapse-Free Survival (GRFS) May Optimize Transplant Decision-Making Process in Haploidentical Stem Cell Transplantation

Author

Lupo-Stanghellini, Maria Teresa, primary, Antonarelli, Gabriele, additional, Lorentino, Francesca, additional, Sala, Elisa, additional, Morelli, Mara, additional, Greco, Raffaella, additional, Marcatti, Magda, additional, Piemontese, Simona, additional, Perini, Tommaso, additional, Assanelli, Andrea Angelo, additional, Carrabba, Matteo Giovanni, additional, Forcina, Alessandra, additional, Dalto, Serena Camilla, additional, Mastaglio, Sara, additional, Marktel, Sarah, additional, Lunghi, Francesca, additional, Guggiari, Elena, additional, Giglio, Fabio, additional, Pavesi, Francesca, additional, Vago, Luca, additional, Bernardi, Massimo, additional, Corti, Consuelo, additional, Peccatori, Jacopo, additional, and Ciceri, Fabio, additional

Published
2016
Full Text
View/download PDF

43. Multiple Inhibitory Receptors Are Expressed on Central Memory and Memory Stem T Cells Infiltrating the Bone Marrow of AML Patients Relapsing after Allo-HSCT

Author

Noviello, Maddalena, primary, Manfredi, Francesco, additional, Perini, Tommaso, additional, Oliveira, Giacomo, additional, Cortesi, Filippo, additional, Toffalori, Cristina, additional, Gambacorta, Valentina, additional, Bondanza, Attilio, additional, Greco, Raffaella, additional, Peccatori, Jacopo, additional, Casorati, Giulia, additional, Dellabona, Paolo, additional, Cieri, Nicoletta, additional, Vago, Luca, additional, Ciceri, Fabio, additional, and Bonini, Chiara, additional

Published
2016
Full Text
View/download PDF

44. Facing the Rising Tide of Multidrug Resistant Gram-Negative Pathogens in Allogeneic HSCT with Nanosphere's Verigene® System

Author

Greco, Raffaella, primary, Barbanti, Maria Chiara, additional, Mancini, Nicasio, additional, Infurnari, Laura, additional, Pasciuta, Renée, additional, Forcina, Alessandra, additional, Vago, Luca, additional, Giglio, Fabio, additional, Messina, Carlo, additional, Morelli, Mara, additional, Perini, Tommaso, additional, Girlanda, Stefania, additional, Carrabba, Matteo G, additional, Lupo Stanghellini, Maria Teresa, additional, Marktel, Sarah, additional, Assanelli, Andrea, additional, Bernardi, Massimo, additional, Corti, Consuelo, additional, Peccatori, Jacopo, additional, Clementi, Massimo, additional, and Ciceri, Fabio, additional

Published
2015
Full Text
View/download PDF

45. Low-Dose Antithymocyte Globulin, Post-Transplant Cyclophosphamide and Sirolimus As Graft-Versus-Host Disease Prophylaxis in Unrelated Donor Transplants

Author

Greco, Raffaella, primary, Peccatori, Jacopo, additional, Crucitti, Lara, additional, Vago, Luca, additional, Cieri, Nicoletta, additional, Giglio, Fabio, additional, Lupo Stanghellini, Maria Teresa, additional, Morelli, Mara, additional, Barbanti, Maria Chiara, additional, Piemontese, Simona, additional, Perini, Tommaso, additional, Sala, Elisa, additional, Pavesi, Francesca, additional, Messina, Carlo, additional, Milani, Raffaella, additional, Marcatti, Magda, additional, Marktel, Sarah, additional, Carrabba, Matteo G, additional, Bernardi, Massimo, additional, Corti, Consuelo, additional, Assanelli, Andrea, additional, Bonini, Chiara, additional, and Ciceri, Fabio, additional

Published
2015
Full Text
View/download PDF

46. A plastic SQSTM1/p62-dependent autophagic reserve maintains proteostasis and determines proteasome inhibitor susceptibility in multiple myeloma cells

Author

Milan, Enrico, primary, Perini, Tommaso, additional, Resnati, Massimo, additional, Orfanelli, Ugo, additional, Oliva, Laura, additional, Raimondi, Andrea, additional, Cascio, Paolo, additional, Bachi, Angela, additional, Marcatti, Magda, additional, Ciceri, Fabio, additional, and Cenci, Simone, additional

Published
2015
Full Text
View/download PDF

47. Ywhae Located on Chromosome 17p13 Promotes Myeloma Cells Proliferation Via Induction of Anti-Apoptosis and Survival Signaling Pathways

Author

Xu, Yan, Fulciniti, Mariateresa, Samur, Mehmet Kemal, Szalat, Raphael, Ho, Matthew, Lopez, Michael A, Li, Na, Lin, Jianhong, Perini, Tommaso, Talluri, Srikanth, Liu, Jiye, Wen, Kenneth, Bianchi, Giada, Zhang, Li, Xing, Lijie, Gang, An, Lin, Liang, Tai, Yu-Tzu, Qiu, Lugui, Anderson, Kenneth C, and Munshi, Nikhil

Published
2017
Full Text
View/download PDF

48. Graft-Versus-Host Disease after Haploidentical Stem Cell Transplantation in High Risk Haematological Diseases: A 10-Years Evaluation at San Raffaele Scientific Institute

Author

Lupo-Stanghellini, Maria Teresa, primary, Orsini, Alessia, additional, Crucitti, Lara, additional, Crocchiolo, Roberto, additional, Greco, Raffaella, additional, Forcina, Alessandra, additional, Guggiari, Elena, additional, Lunghi, Francesca, additional, Girlanda, Stefania, additional, Perini, Tommaso, additional, Pavesi, Francesca, additional, Marktel, Sarah, additional, Assanelli, Andrea, additional, Marcatti, Magda, additional, Carrabba, Matteo G, additional, Giglio, Fabio, additional, Bernardi, Massimo, additional, Corti, Consuelo, additional, Peccatori, Jacopo, additional, Bonini, Chiara, additional, Bordignon, Claudio, additional, and Ciceri, Fabio, additional

Published
2014
Full Text
View/download PDF

49. B Cell Transcriptional Coactivator POU2AF1(BOB-1) Is an Early Transcription Factor Modulating the Protein Synthesis and Ribosomal Biogenesis in Multiple Myeloma: With Therapeutic Implication

Author

Chyra, Zuzana, Samur, Mehmet K., Aktas-Samur, Anil, Yao, Yao, Derebail, Sanika, Perini, Tommaso, Xu, Yan, Morelli, Eugenio, Adamia, Sophia, Park, Woojun D, Charles, Lin, Shirasaki, Ryosuke, Shammas, Masood A., Mitsiades, Constantine S., Hajek, Roman, Fulciniti, Mariateresa, and Munshi, Nikhil C.

Abstract

Multiple Myeloma (MM) is a malignancy driven by numerous genetic and epigenetic alterations. Recurrent IgH translocations, somatic mutations and copy number abnormalities all contribute to myelomagenesis, however true drivers of the disease have not been well defined.

Published
2021
Full Text
View/download PDF

50. Functional Role of Linc-RNAs in Multiple Myeloma: Linc-MIR17HG Affects Fatty Acid Biosynthesis Viatranscriptional Regulation of ACC1 with Potential Therapeutic Implications

Author

Morelli, Eugenio, Fulciniti, Mariateresa, Samur, Mehmet Kemal, Scionti, Francesca, Gulla, Annamaria, Amodio, Nicola, Bianchi, Giada, Perini, Tommaso, Federico, Cinzia, Lopez, Michael A, Di Martino, Maria Teresa, Tagliaferri, Pierosandro, Tassone, Pierfrancesco, Anderson, Kenneth, and Munshi, Nikhil

Abstract

Besides the well described function of RNA to produce proteins, a large volume of transcribed product has non-coding function. A recent analysis of RNA repertoire has identified a family of non-coding transcripts with sequence longer than 200 nucleotides, the long intergenic non-coding RNAs (lincRNAs). Although lincRNAs have been considered to provide regulatory functions, their precise role in cellular biology remains unclear. Using our RNA-seq data from 360 newly-diagnosed patients and 18 normal plasma cells, we have recently described the landscape of lincRNAs in multiple myeloma (MM) and reported their role as independent risk predictors for survival outcome.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results